Oric Pharmaceuticals (NASDAQ:ORIC) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
ORIC® Pharmaceuticals Provides Operational Highlights for 2025 and Anticipated Upcoming Milestones
Oric Pharmaceuticals (NASDAQ:ORIC) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Oric Pharmaceuticals (NASDAQ:ORIC) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
ORIC® Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference